Millennium Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43.3M Sell
199,200
-80,900
-29% -$17.9M 0.02% 929
2025
Q4
$64M Sell
280,100
-111,800
-29% -$25.5M 0.03% 643
2025
Q3
$90.7M Buy
391,900
+22,900
+6% +$4.66M 0.04% 493
2025
Q2
$68.5M Sell
369,000
-334,100
-48% -$62.1M 0.03% 625
2025
Q1
$147M Buy
703,100
+244,500
+53% +$47.5M 0.08% 233
2024
Q4
$81.5M Buy
458,600
+20,700
+5% +$3.81M 0.04% 488
2024
Q3
$86.5M Sell
437,900
-332,500
-43% -$62.1M 0.04% 507
2024
Q2
$132M Buy
770,400
+230,300
+43% +$38.1M 0.06% 318
2024
Q1
$98.4M Sell
540,100
-496,300
-48% -$85.5M 0.04% 463
2023
Q4
$161M Sell
1,036,400
-564,400
-35% -$82.3M 0.07% 244
2023
Q3
$239M Buy
1,600,800
+651,100
+69% +$95.6M 0.12% 114
2023
Q2
$128M Sell
949,700
-240,800
-20% -$35.3M 0.06% 255
2023
Q1
$190M Sell
1,190,500
-435,200
-27% -$66.5M 0.11% 126
2022
Q4
$263M Buy
1,625,700
+664,700
+69% +$102M 0.15% 91
2022
Q3
$129M Buy
961,000
+217,800
+29% +$31.3M 0.08% 217
2022
Q2
$114M Sell
743,200
-179,300
-19% -$27.4M 0.07% 244
2022
Q1
$150M Buy
922,500
+40,800
+5% +$5.93M 0.08% 189
2021
Q4
$119M Buy
881,700
+232,400
+36% +$27.5M 0.06% 287
2021
Q3
$70M Sell
649,300
-4,900
-0.7% -$560K 0.04% 461
2021
Q2
$73.7M Buy
654,200
+139,400
+27% +$15.7M 0.05% 429
2021
Q1
$55.7M Sell
514,800
-408,900
-44% -$43.7M 0.04% 446
2020
Q4
$99M Buy
923,700
+407,100
+79% +$39.1M 0.07% 211
2020
Q3
$45.2K Buy
516,600
+140,600
+37% +$13.2M 0.06% 364
2020
Q2
$36.9M Buy
376,000
+231,400
+160% +$20.4M 0.05% 424
2020
Q1
$11M Sell
144,600
-396,900
-73% -$33.8M 0.02% 793
2019
Q4
$47.9M Sell
541,500
-174,800
-24% -$14.5M 0.06% 386
2019
Q3
$54.2M Buy
716,300
+313,800
+78% +$21.5M 0.09% 282
2019
Q2
$29.3M Sell
402,500
-297,500
-43% -$23.4M 0.04% 574
2019
Q1
$56.4M Buy
700,000
+500,000
+250% +$40.9M 0.08% 306
2018
Q4
$18.4M Buy
+200,000
New +$17.6M 0.03% 749
2018
Q3
Sell
-200,000
Closed -$18.5M 3844
2018
Q2
$18.5M Hold
200,000
0.02% 904
2018
Q1
$18.9M Buy
200,000
+50,000
+33% +$5.49M 0.03% 906
2017
Q4
$14.5M Sell
150,000
-150,000
-50% -$14.1M 0.02% 1093
2017
Q3
$26.7M Buy
+300,000
New +$22.8M 0.04% 634
2017
Q2
Sell
-25,000
Closed -$1.63M 3402
2017
Q1
$1.63M Buy
+25,000
New +$1.57M ﹤0.01% 2120
2016
Q4
Sell
-354,400
Closed -$22.4M 3290
2016
Q3
$22.4M Buy
+354,400
New +$22.9M 0.04% 533
2016
Q1
Sell
-50,000
Closed -$2.01M 3213
2015
Q4
$2.01M Sell
50,000
-100,000
-67% -$5.76M ﹤0.01% 1922
2015
Q3
$8.16M Hold
150,000
0.02% 1052
2015
Q2
$10.1M Hold
150,000
0.02% 971
2015
Q1
$8.78M Sell
150,000
-50,000
-25% -$3.02M 0.02% 1092
2014
Q4
$8.4M Buy
200,000
+133,900
+203% +$8.44M 0.02% 1100
2014
Q3
$2.35M Buy
66,100
+62,100
+1,553% +$3.45M 0.01% 1761
2014
Q2
$226K Buy
+4,000
New +$210K ﹤0.01% 3051
2014
Q1
Sell
-159,700
Closed -$8.43M 3398
2013
Q4
$8.43M Buy
+159,700
New +$7.85M 0.03% 821
2013
Q3
Sell
-170,400
Closed -$7.04M 3254
2013
Q2
$7.04M Buy
+170,400
New +$7.45M 0.02% 820

Other funds holding ABBV

Millennium Management's ABBV Position: Q1 2026 in Review

Millennium Management increased its AbbVie (ABBV) stake by 3,297% in Q1 2026, buying an estimated $145M and bringing the position to 675,757 shares worth $147M. The position accounts for 0.06% of the portfolio, ranked #303.

Millennium Management first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $467M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Millennium Management held 675,757 shares of AbbVie worth $147M as of Q1 2026.
  • Millennium Management bought 655,864 AbbVie shares in Q1 2026, an estimated $145M.
  • AbbVie made up 0.06% of Millennium Management's portfolio in Q1 2026, its #303 holding.
  • Millennium Management first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • Millennium Management's AbbVie position peaked at $467M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.